FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084201369> ?p ?o ?g. }

• W2084201369 endingPage "370" @default.
• W2084201369 startingPage "365" @default.
• W2084201369 abstract "Fabry disease is a lysosomal storage disorder caused by a deficiency of the lysosomal enzyme α-galactosidase A (α-gal A). This enzymatic defect results in the accumulation of the glycosphingolipid globotriaosylceramide (Gb 3 ; also referred to as ceramidetrihexoside) throughout the body. To investigate the effects of purified α-gal A, 10 patients with Fabry disease received a single i.v. infusion of one of five escalating dose levels of the enzyme. The objectives of this study were: ( i ) to evaluate the safety of administered α-gal A, ( ii ) to assess the pharmacokinetics of i.v.-administered α-gal A in plasma and liver, and ( iii ) to determine the effect of this replacement enzyme on hepatic, urine sediment and plasma concentrations of Gb 3 . α-Gal A infusions were well tolerated in all patients. Immunohistochemical staining of liver tissue approximately 2 days after enzyme infusion identified α-gal A in several cell types, including sinusoidal endothelial cells, Kupffer cells, and hepatocytes, suggesting diffuse uptake via the mannose 6-phosphate receptor. The tissue half-life in the liver was greater than 24 hr. After the single dose of α-gal A, nine of the 10 patients had significantly reduced Gb 3 levels both in the liver and shed renal tubular epithelial cells in the urine sediment. These data demonstrate that single infusions of α-gal A prepared from transfected human fibroblasts are both safe and biochemically active in patients with Fabry disease. The degree of substrate reduction seen in the study is potentially clinically significant in view of the fact that Gb 3 burden in Fabry patients increases gradually over decades. Taken together, these results suggest that enzyme replacement is likely to be an effective therapy for patients with this metabolic disorder." @default.
• W2084201369 created "2016-06-24" @default.
• W2084201369 creator A5001000588 @default.
• W2084201369 creator A5002350476 @default.
• W2084201369 creator A5004452100 @default.
• W2084201369 creator A5011133836 @default.
• W2084201369 creator A5016277737 @default.
• W2084201369 creator A5016593142 @default.
• W2084201369 creator A5020271486 @default.
• W2084201369 creator A5021642818 @default.
• W2084201369 creator A5022298202 @default.
• W2084201369 creator A5023443595 @default.
• W2084201369 creator A5024269973 @default.
• W2084201369 creator A5024348136 @default.
• W2084201369 creator A5027336337 @default.
• W2084201369 creator A5027953825 @default.
• W2084201369 creator A5036359910 @default.
• W2084201369 creator A5060798195 @default.
• W2084201369 creator A5061538833 @default.
• W2084201369 creator A5064650178 @default.
• W2084201369 creator A5065856515 @default.
• W2084201369 creator A5068774111 @default.
• W2084201369 creator A5086685253 @default.
• W2084201369 creator A5087586693 @default.
• W2084201369 date "2000-01-04" @default.
• W2084201369 modified "2023-10-17" @default.
• W2084201369 title "Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease" @default.
• W2084201369 cites W1529968415 @default.
• W2084201369 cites W190772732 @default.
• W2084201369 cites W1910396363 @default.
• W2084201369 cites W1963920970 @default.
• W2084201369 cites W1985634863 @default.
• W2084201369 cites W1990381519 @default.
• W2084201369 cites W2018289835 @default.
• W2084201369 cites W202117024 @default.
• W2084201369 cites W2023136400 @default.
• W2084201369 cites W2026507072 @default.
• W2084201369 cites W2035161172 @default.
• W2084201369 cites W2040283218 @default.
• W2084201369 cites W2040721946 @default.
• W2084201369 cites W2046864442 @default.
• W2084201369 cites W2048198289 @default.
• W2084201369 cites W2071463936 @default.
• W2084201369 cites W2081153395 @default.
• W2084201369 cites W2087185786 @default.
• W2084201369 cites W2095017414 @default.
• W2084201369 cites W2100837269 @default.
• W2084201369 cites W2101108802 @default.
• W2084201369 cites W2140596567 @default.
• W2084201369 cites W2184800492 @default.
• W2084201369 cites W2186595494 @default.
• W2084201369 cites W2317081948 @default.
• W2084201369 cites W2338493443 @default.
• W2084201369 cites W2341838831 @default.
• W2084201369 cites W295502310 @default.
• W2084201369 doi "https://doi.org/10.1073/pnas.97.1.365" @default.
• W2084201369 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/26669" @default.
• W2084201369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10618424" @default.
• W2084201369 hasPublicationYear "2000" @default.
• W2084201369 type Work @default.
• W2084201369 sameAs 2084201369 @default.
• W2084201369 citedByCount "327" @default.
• W2084201369 countsByYear W20842013692012 @default.
• W2084201369 countsByYear W20842013692013 @default.
• W2084201369 countsByYear W20842013692014 @default.
• W2084201369 countsByYear W20842013692015 @default.
• W2084201369 countsByYear W20842013692016 @default.
• W2084201369 countsByYear W20842013692017 @default.
• W2084201369 countsByYear W20842013692018 @default.
• W2084201369 countsByYear W20842013692019 @default.
• W2084201369 countsByYear W20842013692020 @default.
• W2084201369 countsByYear W20842013692021 @default.
• W2084201369 countsByYear W20842013692022 @default.
• W2084201369 countsByYear W20842013692023 @default.
• W2084201369 crossrefType "journal-article" @default.
• W2084201369 hasAuthorship W2084201369A5001000588 @default.
• W2084201369 hasAuthorship W2084201369A5002350476 @default.
• W2084201369 hasAuthorship W2084201369A5004452100 @default.
• W2084201369 hasAuthorship W2084201369A5011133836 @default.
• W2084201369 hasAuthorship W2084201369A5016277737 @default.
• W2084201369 hasAuthorship W2084201369A5016593142 @default.
• W2084201369 hasAuthorship W2084201369A5020271486 @default.
• W2084201369 hasAuthorship W2084201369A5021642818 @default.
• W2084201369 hasAuthorship W2084201369A5022298202 @default.
• W2084201369 hasAuthorship W2084201369A5023443595 @default.
• W2084201369 hasAuthorship W2084201369A5024269973 @default.
• W2084201369 hasAuthorship W2084201369A5024348136 @default.
• W2084201369 hasAuthorship W2084201369A5027336337 @default.
• W2084201369 hasAuthorship W2084201369A5027953825 @default.
• W2084201369 hasAuthorship W2084201369A5036359910 @default.
• W2084201369 hasAuthorship W2084201369A5060798195 @default.
• W2084201369 hasAuthorship W2084201369A5061538833 @default.
• W2084201369 hasAuthorship W2084201369A5064650178 @default.
• W2084201369 hasAuthorship W2084201369A5065856515 @default.
• W2084201369 hasAuthorship W2084201369A5068774111 @default.
• W2084201369 hasAuthorship W2084201369A5086685253 @default.
• W2084201369 hasAuthorship W2084201369A5087586693 @default.
• W2084201369 hasBestOaLocation W20842013691 @default.

• next